EGFR and non-small cell lung carcinoma: In addition, a randomized phase II trial comparing molecular-targeted therapy plus LAT to residual lesions versus molecular-targeted therapy alone is ongoing for patients with EGFR-mutated/ALK-rearranged oligometastatic NSCLC (NCT05277844) (Table 1).